Gilead

Ticker

ETILX

$47.37
-0.21%
04/01/2025
Annualized Returns 1
1-Year
-0.02%
5-Year
7.07%
10-Year
9.30%
Since Inception
12.90%
Morningstar Overall 2
Star Ratings
2

Mid-Cap Growth
479 Funds in Category


Unless otherwise noted, all data is as of 12/31/2024. Performance is historical and does not guarantee future results. Investment return and principal value will fluctuate with changing market conditions so that when redeemed, shares may be worth more or less than their original cost. Current performance may be lower or higher than the data quoted. Morningstar ratings are based on risk-adjusted returns.

Fund Objective

Seeks to provide long-term capital appreciation.

About the Fund

A diversified mutual fund representing our "best ideas" for long-term capital appreciation. Historical emphases in small- and mid-cap growth, Health Care and Information Technology.

Fund Distinctives

A Thematic Approach

Seeking to invest in companies best positioned to participate in long-term secular investment themes.

Creating Compelling Value for Society and the Global Common Good

Focused on identifying and investing in companies capable of increasing profitability and growth by serving well the needs of customers, employees, suppliers, communities, the environment, and society broadly.

Designed as a Non-Correlated Source of Return

Portfolio is constructed with goals of high internal diversification and low market correlation.

At a Glance

Benchmarks
Bloomberg US Mid Cap Growth Index 3
Russell Midcap Growth Index 4
Morningstar Classification
Mid-Cap Growth
Total Assets
$2.50 billion
Inception Date
02/02/2010
Number of Holdings
84
Average Market Cap
$34.7 billion
Median Market Cap
$17.0 billion
Distribution Frequency
Annually
Portfolio Turnover Ratio 5
36%
Annual Turnover Range 6
27%-36%
Management Fees
0.97%
Sales Charge 7
None
Other Expenses 8
0.19%
12b-1 Fees
0.00%
Gross Expenses
1.16%
Net Expenses
1.16%
Minimum Investment 9
$100,000
Active Share 10
87%

Performance and Risk

Trailing Returns (%) As of the quarter ending 12/31/2024

Trailing Returns (%) As of the quarter ending 12/31/2024

Eventide Gilead Fund
As of 04/01/2025
YTD
3-month1-year3-year5-year10-yearSince InceptionInception Date
Class I-8.18%0.25-0.02-6.747.079.3012.9002/02/2010
Class A without load-8.25%0.20-0.26-6.976.829.0313.7110/28/2009
Class A with 5.75% load-13.54%-5.57-5.99-8.795.568.3813.2710/28/2009
Class C-8.42%0.00-1.03-7.676.008.2012.8410/28/2009
Class N-8.23%0.22-0.22-6.936.869.0812.4207/08/2008
Benchmarks  
Bloomberg US Mid Cap Growth Index3-5.80%2.7615.762.1510.8210.7410.6307/08/2008
Russell Midcap Growth Index4-6.25%8.1422.104.0411.4711.5411.3507/08/2008

Calendar Year Returns (%)

Calendar Year Returns (%)

2015201620172018201920202021202220232024
Eventide Gilead Fund, Class I-1.941.1233.09-2.3334.1055.4211.64-33.9222.76-0.02
Bloomberg US Mid Cap Growth Index3-0.017.2722.55-6.0034.3432.0618.73-24.0121.1815.76
Russell Midcap Growth Index4-0.207.3325.27-4.7535.4735.5912.73-26.7225.8722.10
Performance is historical and does not guarantee future results. Investment return and principal value will fluctuate with changing market conditions so that when redeemed, shares may be worth more or less than their original cost. Current performance may be lower or higher than the data quoted. Investors cannot directly invest in an index, and unmanaged index returns do not reflect any fees, expenses, or sales charges. The volatility of an index may be materially different than that of the Fund, and investors should not expect the Fund to achieve the same results as a listed index. This material must be read along with the Fund's prospectus, which may be obtained at eventidefunds.com/prospectus. Performance data current to the most recent month-end may be obtained by calling 1-877-771-EVEN (3836).

The returns shown do not reflect the deduction in taxes that a shareholder would pay on fund distributions or on the redemption of fund shares. Because of ongoing market volatility, fund performance may be subject to substantial short-term changes. Performance figures greater than 1 year are annualized.

Morningstar Ratings 2

Morningstar ratings are based on risk-adjusted returns. Morningstar rankings are based on total returns.

Overall
479 Funds in Category
3 Year
1
94% Percentile of 479 Funds
5 Year
2
83% Percentile of 440 Funds
10 Year
2
70% Percentile of 358 Funds

Market Risk 11

Market Risk 11

 
 
Standard Deviation12Beta13Alpha(%)14R-Squared(%)15
 
 
3-yrInception163-yrInception163-yrInception163-yrInception16
Eventide Gilead Fund, Class I22.1619.900.991.08-8.86-0.3090.1186.51
Bloomberg US Mid Cap Growth Index321.2317.121.001.00--100100
Russell Midcap Growth Index422.4717.571.041.012.090.3497.1997.89

Portfolio 17

Top 10 Holdings

Holding Weight (28.08%)
Xometry Inc
AI-enabled marketplace for on-demand manufacturing
4.39%
The Trade Desk Inc
Digital advertising platform for display, social, and video campaigns
3.37%
Verona Pharma PLC
Develops new therapies for severe respiratory diseases, including COPD, asthma, and cystic fibrosis
3.00%
Toast Inc
Develops cloud software to equip restaurants to thrive
2.93%
Global-e Online Ltd
Develops end-to-end cross-border platforms for eBusiness
2.74%
Guardant Health Inc
Cell diagnostics for cancer patients
2.40%
Trane Technologies PLC
HVAC systems for energy efficiency and reduced carbon emissions
2.39%
Old Dominion Freight Line Inc
Inter-regional and multi-regional motor carrier
2.36%
Monday.com Ltd
Platform for streamlining team collaboration, project management, and productivity
2.34%
Scholar Rock
Novel therapeutics for neuromuscular disorders and obesity
2.16%

Portfolio Manager

Finny Kuruvilla, MD, PhD

Co-Chief Investment Officer, Senior Portfolio Manager, Managing Director, Founding Member

Finny Kuruvilla, MD, PhD, serves as Co-Chief Investment Officer and Senior Portfolio Manager for Eventide. He serves as the Lead Portfolio Manager for Eventide’s Strategic Growth, Healthcare & Life Sciences, and Technology Strategies. He also is a Managing Director for Eventide Ventures, as well as a Founding Member of Eventide.

Dr. Kuruvilla has a background in healthcare, statistics, and investing. Concurrent with his early years at Eventide, he was a Principal at Clarus Ventures, a healthcare and life sciences venture capital firm subsequently acquired by Blackstone. Earlier in his career, Dr. Kuruvilla was a postdoctoral research fellow at the Broad Institute of Harvard and MIT, where he led the development of a new microarray between the Broad Institute and a publicly-traded company Affymetrix. Prior to his investing career, Dr. Kuruvilla was resident, chief resident, and fellow at the Brigham and Women’s Hospital and Boston Children’s Hospital.

Dr. Kuruvilla holds an MD from Harvard Medical School, a PhD in Chemistry and Chemical Biology from Harvard University, a SM in Electrical Engineering and Computer Science from MIT, and a BS in Chemistry from Caltech.

Literature

Impact the world for good

  1. Returns are for Class I as of 12/31/2024 with an inception date of 02/02/2010. Performance is historical and does not guarantee future results. Investment return and principal value will fluctuate with changing market conditions so that when redeemed, shares may be worth more or less than their original cost. Current performance may be lower or higher than the data quoted.
  2. Past performance is no guarantee of future results.

    The Morningstar Rating™ for funds, or ‘star rating’, is calculated for managed products (including mutual funds, variable annuity and variable life subaccounts, exchange-traded funds, closed-end funds, and separate accounts) with at least a three-year history. Exchange-traded funds and open-ended mutual funds are considered a single population for comparative purposes. It is calculated based on a Morningstar Risk-Adjusted Return measure that accounts for variation in a managed product’s monthly excess performance, placing more emphasis on downward variations and rewarding consistent performance. The Morningstar Rating does not include any adjustment for sales loads. The top 10% of products in each product category receive 5 stars, the next 22.5% receive 4 stars, the next 35% receive 3 stars, the next 22.5% receive 2 stars, and the bottom 10% receive 1 star. The Overall Morningstar Rating for a managed product is derived from a weighted average of the performance figures associated with its three-, five-, and 10-year (if applicable) Morningstar Rating metrics. The weights are: 100% three-year rating for 36-59 months of total returns, 60% five-year rating/40% three-year rating for 60-119 months of total returns, and 50% 10-year rating/30% five-year rating/20% three-year rating for 120 or more months of total returns. While the 10-year overall star rating formula seems to give the most weight to the 10- year period, the most recent three-year period actually has the greatest impact because it is included in all three rating periods. Ratings are determined monthly and subject to change.

    % Rank in Category is the fund’s percentile rank for the specified time period relative to all funds that have the same Morningstar category. The highest (or most favorable) percentile rank is 1 and the lowest (or least favorable) percentile rank is 100. The top-performing fund in a category will always receive a rank of 1. Percentile ranks within categories are most useful in those categories that have a large number of funds.

    © 2025 Morningstar. All Rights Reserved. Morningstar is an independent provider of financial information. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete, or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.

  3. On 06/30/2024, the Fund's primary benchmark to compare its performance changed from the Russell Midcap Growth Index to the Bloomberg US Mid Cap Growth Index because the Fund's Adviser believes it provides more value per cost while maintaining high standards of accuracy, relevance, and reliability. The Bloomberg US Mid Cap Growth Index is a float market-cap-weighted index based on an equal-weighted combination of four factors: earnings yield, valuation, dividend yield, and growth. The constituents consist of the lower 800 in capitalization of the Bloomberg 1000 Index, which is a float market-cap-weighted benchmark of the 1000 most highly capitalized US companies. Source: Bloomberg Index Services Limited. Bloomberg® is a trademark and service mark of Bloomberg Finance L.P. and its affiliates (collectively "Bloomberg"). Bloomberg or Bloomberg's licensors own all proprietary rights in the Bloomberg Indices. Neither Bloomberg nor Bloomberg's licensors approves or endorses this material, or guarantees the accuracy or completeness of any information herein, or makes any warranty, express or implied, as to the results to be obtained therefrom and, to the maximum extent allowed by law, neither shall have any liability or responsibility for injury or damages arising in connection therewith. Investors cannot directly invest in an index, and unmanaged index returns do not reflect any fees, expenses, or sales charges. The volatility of an index may be materially different than that of the Fund, and investors should not expect the Fund to achieve the same results as a listed index.
  4. The Russell Midcap Growth Index measures the performance of the U.S. equity mid-cap growth segment. Investors cannot directly invest in an index, and unmanaged index returns do not reflect any fees, expenses, or sales charges. The volatility of an index may be materially different than that of the Fund, and investors should not expect the Fund to achieve the same results as a listed index.
  5. For the Fund's fiscal year ending 06/30/2024.

    Portfolio turnover is the percentage of the portfolio that was bought or sold (lesser) during a fiscal year. A higher portfolio turnover may indicate higher transaction costs for the Fund and may result in higher taxes for investors.

  6. The range shows the highest and lowest turnover ratio reported in the Annual Report during the last three fiscal years ending 06/30/2024.

    Portfolio turnover is the percentage of the portfolio that was bought or sold (lesser) during a fiscal year. A higher portfolio turnover may indicate higher transaction costs for the Fund and may result in higher taxes for investors.

  7. Other expenses that apply to a continued investment in the Fund are described in the Fund's prospectus.
  8. Refer to the Fund's SAI for definition of Other Expenses.
  9. Effective 06/01/2022, Class I shares purchased directly from the Funds are not subject to the minimum initial or subsequent investment requirements.
  10. Fund information is as of 12/31/2024. Benchmark is Bloomberg US Mid Cap Growth Index, and benchmark information is as of 12/31/2024. Source: Bloomberg. Active Share is the percentage of fund holdings that is different from the benchmark holdings. A higher percentage indicates a greater difference from the benchmark.
  11. Source: © Morningstar, Inc. (2025). All rights reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. The performance and risk factor comparisons are against the Bloomberg US Mid Cap Growth Index. The Bloomberg US Mid Cap Growth Index is a float market-cap-weighted index based on an equal-weighted combination of four factors: earnings yield, valuation, dividend yield, and growth. The constituents consist of the lower 800 in capitalization of the Bloomberg 1000 Index, which is a float market-cap-weighted benchmark of the 1000 most highly capitalized US companies. Source: Bloomberg Index Services Limited. Bloomberg® is a trademark and service mark of Bloomberg Finance L.P. and its affiliates (collectively “Bloomberg”). Bloomberg or Bloomberg’s licensors own all proprietary rights in the Bloomberg Indices. Neither Bloomberg nor Bloomberg’s licensors approves or endorses this material, or guarantees the accuracy or completeness of any information herein, or makes any warranty, express or implied, as to the results to be obtained therefrom and, to the maximum extent allowed by law, neither shall have any liability or responsibility for injury or damages arising in connection therewith. Prior to Q4 2020, Class N shares were displayed.
  12. Standard Deviation of return measures the amount of variation in historical performance from period to period.
  13. Beta is a measure of the volatility of a fund relative to the Index. A beta greater than 1 is more volatile than the Index.
  14. Alpha is a measure of performance on a risk-adjusted basis. It takes the volatility (price risk) of a fund and compares its risk-adjusted performance to the Index. Any excess return of a fund relative to the return of the Index is a fund’s alpha.
  15. R-Squared is a measure of how a fund’s performance correlates with the Index’s performance and it can help assess how likely it is that beta is statistically significant.
  16. Annualized since inception figures use an inception date of 03/01/2010 and not the actual inception date of 02/02/2010 as only full month data is used in Market Risk calculations.
  17. Allocation percentages and holdings are subject to change at any time, are subject to risks discussed in the Funds prospectus, and should not be considered investment advice.
    Assets labeled Cash/Other may include cash, cash equivalents, money market funds, impact bonds, and options. Impact bonds, if invested, fund business models that strive to have significant social or environmental effects.
    Due to rounding, numbers may not add up to 100.
    Top Holdings are based on percentage of net assets and do not include cash/money market funds/equivalents.
    Portfolio Composition Source: © Morningstar, Inc. (2025). All rights reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
  18. This chart is for illustrative purposes and assumes that a $10,000 investment was made on the Fund’s inception date of 07/08/2008 and that all dividends and capital gains were reinvested. Hypothetical performance often shows markedly better results than actual management and should not be the basis for an investment decision. A variety of factors could impact investment decision making or otherwise cause differences between the hypothetical performance and actual investor returns. Performance since inception to 02/01/2010 is an estimate based on the Fund’s Class N shares, adjusted for fees. Beginning on 02/02/2010, the Fund’s Class I share performance is used. Compares the Eventide Gilead Fund Class I’s performance to index performance over the periods shown. Performance will differ for other fund classes, based upon fees and commissions. Prior to Q4 2020, Class N shares were displayed.
    The returns shown do not reflect the deduction of taxes that a shareholder would pay on fund distributions or on the redemption of fund shares. Because of ongoing market volatility, fund performance may be subject to substantial short-term changes.
    Performance is historical and does not guarantee future results. Investment return and principal value will fluctuate with changing market conditions so that when redeemed, shares may be worth more or less than their original cost. Current performance may be lower or higher than the data quoted. Performance data current to the most recent month-end may be obtained by calling 1-877-771-EVEN (3836).


Eventide 1561-2179 - 04/02/2025 09:10am